Pfizer invests in Valneva, updates agreement on Lyme disease vaccine
Under a new deal, Pfizer buys 8.1% of the French firm’s shares, with proceeds going to an upcoming phase III trial of the word’s only Lyme disease vaccine candidate in development.
by christian bundgaard, translated by daniel pedersen
Back in 2020, Valneva and US-based Pfizer partnered up on the development of the French firm’s vaccine candidate, VLA15, for Lyme disease, also known as Lyme borreliosis.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
EU to terminate vaccine agreement with Valneva
For subscribers
